๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain

โœ Scribed by F. Moolenaar; W. J. Meijler; H. W. Frijlink; J. Visser; J. H. Proost

Publisher
Springer
Year
2000
Tongue
English
Weight
113 KB
Volume
56
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Controlled-release morphine tablets in p
Controlled-release morphine tablets in patients with chronic cancer pain : A narrative review of controlled clinical trials
โœ Carol A. Warfield ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 143 KB ๐Ÿ‘ 2 views

## Background: Controlled-release (cr) morphine tablets have become routine therapy in the management of cancer pain. compared with immediate-release (ir) morphine, this formulation provides the benefit of dosing every 12 hours. ## Methods: This study reviewed the 10 published, well controlled, r

Comparative clinical efficacy and safety
Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain
โœ Neil A. Hagen; Najib Babul ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 210 KB ๐Ÿ‘ 2 views

Fredphone, each given every 12 hours for 7 days. Pain intensity, nausea, and sedation erick, Pickering, Ontario, Canada. were assessed by patients four times daily, and breakthrough analgesia was recorded. ## RESULTS. Thirty-one patients completed the study (18 women, 13 men; mean age, 56 { 3 ye